Integra Lifesciences Hldgs Cp Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Integra Lifesciences Hldgs Cp has an operating margin of 1.8%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 9/100, suggesting thin profitability after operating expenses. This is down from 7.2% the prior year.
Integra Lifesciences Hldgs Cp's revenue grew a modest 4.5% year-over-year to $1.6B. This slow but positive growth earns a score of 41/100.
Integra Lifesciences Hldgs Cp carries a low D/E ratio of 0.49, meaning only $0.49 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.
Integra Lifesciences Hldgs Cp's current ratio of 1.17 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.
While Integra Lifesciences Hldgs Cp generated $129.4M in operating cash flow, capex of $104.4M consumed most of it, leaving $25.0M in free cash flow. This results in a low score of 8/100, reflecting heavy capital investment rather than weak cash generation.
Integra Lifesciences Hldgs Cp scores 1.01, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Integra Lifesciences Hldgs Cp passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Integra Lifesciences Hldgs Cp generates $-18.63 in operating cash flow ($129.4M OCF vs -$6.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Integra Lifesciences Hldgs Cp earns $0.4 in operating income for every $1 of interest expense ($28.4M vs $70.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Integra Lifesciences Hldgs Cp (IART) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Integra Lifesciences Hldgs Cp generated $1.6B in revenue in fiscal year 2024. This represents an increase of 4.5% from the prior year.
Integra Lifesciences Hldgs Cp's EBITDA was $92.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 44.1% from the prior year.
Integra Lifesciences Hldgs Cp generated $25.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 65.8% from the prior year.
Integra Lifesciences Hldgs Cp reported -$6.9M in net income in fiscal year 2024. This represents a decrease of 110.3% from the prior year.
Integra Lifesciences Hldgs Cp earned $-0.09 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 110.7% from the prior year.
Integra Lifesciences Hldgs Cp held $246.4M in cash against $760.5M in long-term debt as of fiscal year 2024.
Integra Lifesciences Hldgs Cp's gross margin was 54.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the prior year.
Integra Lifesciences Hldgs Cp's operating margin was 1.8% in fiscal year 2024, reflecting core business profitability. This is down 5.5 percentage points from the prior year.
Integra Lifesciences Hldgs Cp's net profit margin was -0.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 4.8 percentage points from the prior year.
Integra Lifesciences Hldgs Cp invested $115.4M in research and development in fiscal year 2024. This represents an increase of 10.7% from the prior year.
Integra Lifesciences Hldgs Cp spent $52.5M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 80.9% from the prior year.
Integra Lifesciences Hldgs Cp invested $104.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 56.2% from the prior year.
IART Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $402.1M-3.3% | $415.6M+8.6% | $382.7M-13.6% | $442.6M+5.9% | $418.2M+13.4% | $368.9M-7.1% | $397.0M+3.8% | $382.4M |
| Cost of Revenue | $195.1M-5.4% | $206.3M+9.6% | $188.2M-2.8% | $193.6M+0.7% | $192.3M+18.6% | $162.0M-5.0% | $170.5M+3.9% | $164.1M |
| Gross Profit | $207.0M-1.1% | $209.3M+7.7% | $194.4M-21.9% | $249.1M+10.2% | $225.9M+9.2% | $206.8M-8.7% | $226.5M+3.7% | $218.3M |
| R&D Expenses | $22.5M-16.8% | $27.0M+9.2% | $24.7M-20.8% | $31.2M+4.8% | $29.8M+10.4% | $27.0M+11.0% | $24.3M-8.7% | $26.6M |
| SG&A Expenses | $169.0M-6.0% | $179.9M-0.9% | $181.5M+1.7% | $178.5M-8.7% | $195.5M+17.9% | $165.8M+1.6% | $163.1M+0.7% | $161.9M |
| Operating Income | $11.8M+102.3% | -$512.7M-3208.2% | -$15.5M-143.5% | $35.6M+1276.2% | -$3.0M-176.4% | $4.0M-89.0% | $36.0M+35.6% | $26.6M |
| Interest Expense | $22.7M+8.0% | $21.0M+11.8% | $18.8M-0.9% | $19.0M+1.8% | $18.7M+36.9% | $13.6M-0.9% | $13.8M+5.3% | $13.1M |
| Income Tax | -$1.4M+97.0% | -$46.9M-888.4% | -$4.7M-252.7% | $3.1M+211.6% | -$2.8M-42.8% | -$1.9M-121.6% | $9.0M+1116.2% | -$888K |
| Net Income | -$5.4M+98.9% | -$484.1M-1813.9% | -$25.3M-230.1% | $19.4M+256.7% | -$12.4M-278.0% | -$3.3M-116.5% | $19.8M+1.7% | $19.5M |
| EPS (Diluted) | $-0.07+98.9% | $-6.31-1812.1% | $-0.33-232.0% | $0.25+256.3% | $-0.16-300.0% | $-0.04-115.4% | $0.26+8.3% | $0.24 |
IART Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.6B-0.6% | $3.7B-9.5% | $4.1B+0.4% | $4.0B-0.9% | $4.1B-0.1% | $4.1B+7.8% | $3.8B+1.1% | $3.7B |
| Current Assets | $1.1B+0.1% | $1.1B+3.2% | $1.1B+2.4% | $1.1B-2.8% | $1.1B-21.4% | $1.4B+33.8% | $1.1B+3.0% | $1.0B |
| Cash & Equivalents | $232.2M+6.5% | $217.9M-8.9% | $239.1M-3.0% | $246.4M+14.5% | $215.2M-63.6% | $591.9M+114.1% | $276.4M+1.0% | $273.7M |
| Inventory | $489.1M+5.2% | $465.1M+4.4% | $445.4M+3.8% | $429.1M+1.7% | $421.8M+4.5% | $403.4M+3.5% | $389.6M+6.4% | $366.3M |
| Accounts Receivable | $262.2M-7.9% | $284.5M+12.7% | $252.4M-7.3% | $272.4M+0.4% | $271.2M+12.5% | $241.1M-7.0% | $259.3M+1.2% | $256.3M |
| Goodwill | $615.2M-0.2% | $616.4M-44.2% | $1.1B+0.8% | $1.1B-0.7% | $1.1B+6.2% | $1.0B-1.4% | $1.1B+1.9% | $1.0B |
| Total Liabilities | $2.6B-0.8% | $2.6B+4.0% | $2.5B+1.5% | $2.5B-1.9% | $2.5B+2.4% | $2.5B+13.0% | $2.2B+1.6% | $2.2B |
| Current Liabilities | $364.1M-60.8% | $929.8M+1.2% | $918.5M-0.4% | $922.1M+180.9% | $328.3M+8.6% | $302.4M-1.5% | $307.0M-13.7% | $355.7M |
| Long-Term Debt | $736.3M-1.3% | $745.9M-1.3% | $755.6M-0.6% | $760.5M-1.3% | $770.2M-0.6% | $775.0M0.0% | $775.0M0.0% | $775.0M |
| Total Equity | $1.0B-0.1% | $1.0B-31.9% | $1.5B-1.4% | $1.5B+0.7% | $1.5B-4.0% | $1.6B+0.6% | $1.6B+0.5% | $1.6B |
| Retained Earnings | $425.1M-1.3% | $430.5M-52.9% | $914.6M-2.7% | $939.9M+0.9% | $931.2M-1.3% | $943.6M-0.3% | $946.9M+2.1% | $927.0M |
IART Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $40.9M+358.6% | $8.9M+179.2% | -$11.3M-122.2% | $50.7M+25.6% | $40.4M+156.4% | $15.8M-73.2% | $58.8M+119.5% | $26.8M |
| Capital Expenditures | $15.2M-24.8% | $20.1M-30.3% | $28.9M-2.3% | $29.6M-0.4% | $29.7M+92.1% | $15.5M-37.0% | $24.5M+87.6% | $13.1M |
| Free Cash Flow | $25.8M+329.4% | -$11.2M+72.1% | -$40.2M-290.1% | $21.1M+97.7% | $10.7M+3574.9% | $291K-99.1% | $34.2M+149.9% | $13.7M |
| Investing Cash Flow | -$15.6M+28.0% | -$21.6M+39.7% | -$35.9M-745.4% | -$4.2M+98.7% | -$322.2M-497.0% | -$54.0M+5.7% | -$57.2M-643.5% | -$7.7M |
| Financing Cash Flow | -$10.2M+51.5% | -$21.1M-159.8% | $35.4M+594.8% | -$7.2M+92.4% | -$93.7M-126.1% | $358.7M+5305.7% | -$6.9M+86.1% | -$49.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | N/A | N/A | $2.5M-95.1% | $50.0M | $0 | $0-100.0% | $125.0M |
IART Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.5%+1.1pp | 50.4%-0.4pp | 50.8%-5.5pp | 56.3%+2.2pp | 54.0%-2.0pp | 56.1%-1.0pp | 57.0%-0.0pp | 57.1% |
| Operating Margin | 2.9%+126.3pp | -123.4%-119.3pp | -4.0%-12.1pp | 8.1%+8.8pp | -0.7%-1.8pp | 1.1%-8.0pp | 9.1%+2.1pp | 7.0% |
| Net Margin | -1.3%+115.1pp | -116.5%-109.9pp | -6.6%-11.0pp | 4.4%+7.4pp | -3.0%-2.1pp | -0.9%-5.9pp | 5.0%-0.1pp | 5.1% |
| Return on Equity | N/A | N/A | N/A | 1.3% | N/A | N/A | 1.3%+0.0pp | 1.2% |
| Return on Assets | -0.1%+13.1pp | -13.2%-12.6pp | -0.6%-1.1pp | 0.5%+0.8pp | -0.3%-0.2pp | -0.1%-0.6pp | 0.5%0.0pp | 0.5% |
| Current Ratio | 3.14+1.9 | 1.23+0.0 | 1.21+0.0 | 1.17-2.2 | 3.39-1.3 | 4.68+1.2 | 3.45+0.6 | 2.89 |
| Debt-to-Equity | 0.710.0 | 0.72+0.2 | 0.500.0 | 0.490.0 | 0.50+0.0 | 0.480.0 | 0.490.0 | 0.49 |
| FCF Margin | 6.4%+9.1pp | -2.7%+7.8pp | -10.5%-15.3pp | 4.8%+2.2pp | 2.6%+2.5pp | 0.1%-8.5pp | 8.6%+5.0pp | 3.6% |
Similar Companies
Frequently Asked Questions
What is Integra Lifesciences Hldgs Cp's annual revenue?
Integra Lifesciences Hldgs Cp (IART) reported $1.6B in total revenue for fiscal year 2024. This represents a 4.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Integra Lifesciences Hldgs Cp's revenue growing?
Integra Lifesciences Hldgs Cp (IART) revenue grew by 4.5% year-over-year, from $1.5B to $1.6B in fiscal year 2024.
Is Integra Lifesciences Hldgs Cp profitable?
No, Integra Lifesciences Hldgs Cp (IART) reported a net income of -$6.9M in fiscal year 2024, with a net profit margin of -0.4%.
What is Integra Lifesciences Hldgs Cp's earnings per share (EPS)?
Integra Lifesciences Hldgs Cp (IART) reported diluted earnings per share of $-0.09 for fiscal year 2024. This represents a -110.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Integra Lifesciences Hldgs Cp's EBITDA?
Integra Lifesciences Hldgs Cp (IART) had EBITDA of $92.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Integra Lifesciences Hldgs Cp have?
As of fiscal year 2024, Integra Lifesciences Hldgs Cp (IART) had $246.4M in cash and equivalents against $760.5M in long-term debt.
What is Integra Lifesciences Hldgs Cp's gross margin?
Integra Lifesciences Hldgs Cp (IART) had a gross margin of 54.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Integra Lifesciences Hldgs Cp's operating margin?
Integra Lifesciences Hldgs Cp (IART) had an operating margin of 1.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Integra Lifesciences Hldgs Cp's net profit margin?
Integra Lifesciences Hldgs Cp (IART) had a net profit margin of -0.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Integra Lifesciences Hldgs Cp's free cash flow?
Integra Lifesciences Hldgs Cp (IART) generated $25.0M in free cash flow during fiscal year 2024. This represents a -65.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Integra Lifesciences Hldgs Cp's operating cash flow?
Integra Lifesciences Hldgs Cp (IART) generated $129.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Integra Lifesciences Hldgs Cp's total assets?
Integra Lifesciences Hldgs Cp (IART) had $4.0B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Integra Lifesciences Hldgs Cp's capital expenditures?
Integra Lifesciences Hldgs Cp (IART) invested $104.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Integra Lifesciences Hldgs Cp spend on research and development?
Integra Lifesciences Hldgs Cp (IART) invested $115.4M in research and development during fiscal year 2024.
Does Integra Lifesciences Hldgs Cp buy back shares?
Yes, Integra Lifesciences Hldgs Cp (IART) spent $52.5M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
What is Integra Lifesciences Hldgs Cp's current ratio?
Integra Lifesciences Hldgs Cp (IART) had a current ratio of 1.17 as of fiscal year 2024, which is considered adequate.
What is Integra Lifesciences Hldgs Cp's debt-to-equity ratio?
Integra Lifesciences Hldgs Cp (IART) had a debt-to-equity ratio of 0.49 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Integra Lifesciences Hldgs Cp's return on assets (ROA)?
Integra Lifesciences Hldgs Cp (IART) had a return on assets of -0.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Integra Lifesciences Hldgs Cp's Altman Z-Score?
Integra Lifesciences Hldgs Cp (IART) has an Altman Z-Score of 1.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Integra Lifesciences Hldgs Cp's Piotroski F-Score?
Integra Lifesciences Hldgs Cp (IART) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Integra Lifesciences Hldgs Cp's earnings high quality?
Integra Lifesciences Hldgs Cp (IART) has an earnings quality ratio of -18.63x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Integra Lifesciences Hldgs Cp cover its interest payments?
Integra Lifesciences Hldgs Cp (IART) has an interest coverage ratio of 0.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Integra Lifesciences Hldgs Cp?
Integra Lifesciences Hldgs Cp (IART) scores 36 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.